Account
Havas to acquire FullSix Group for $75 million
MUMBAI: The Havas Group has entered into exclusive negotiations with the management of FullSix Group and Motion Equity Partners, in view of acquiring FullSix, a European independent digital communications group.
The transaction estimated at $75 million, expected to close during the month of October, is subject to a consultation process with FullSix staff representatives.
Founded in 1998 in Paris by Marco Tinelli and his partners, FullSix generates gross margin of around €60 million and employs over 600 people based in France, Portugal, the United Kingdom, Spain, the United States and Italy.
The acquisition will be a key growth driver for both groups.
Havas CEO Yannick Bolloré said, “I am delighted to welcome all the FullSix talents into the Havas family. We share common values and we both put innovation and integration at the heart of everything we do. I am confident that Marco and his team will further reinforce Havas’ expertise on behalf of our clients, and that Havas will provide FullSix with a major new source of growth.”
FullSix Group president Marco Tinelli added, “We are happy and proud to be joining the Havas Group. This is an enormous opportunity for the FullSix Group and all its talents and clients. We will continue to drive the market forward, with even greater ambition than before. Havas is a dynamic, entrepreneurial group that will bring us the clout, the network and the talents we need to develop even faster. FullSix will add to and develop the Havas Group’s Digital & Data scope and expertise. We are very close in terms of culture, our knowhow is largely complementary and our ambitions are the same.”
Tinelli will continue as president of the FullSix group and Bolloré will oversee the process of integrating entities into the Group.
Account
BigTrunk Communications wins digital mandate for Soframycin
MUMBAI: BigTrunk Communications, an integrated digital marketing agency known for driving brand transformations across industries, has been awarded the digital marketing mandate for Soframycin, one of India’s most trusted antiseptic cream brands from the EncubeEthicals portfolio. With this collaboration, Soframycin makes its debut into the digital space, aiming to amplify its presence across India through compelling social media narratives and data-led campaigns. BigTrunk will lead the brand’s digital strategy and execution, with a focus on connecting Soframycin’s legacy of trust with today’s health-conscious and digitally engaged audience.
Soframycin has been a household name for generations, widely recognized for its efficacy in treating cuts, burns, and wounds. Backed by the scientific rigor and pharmaceutical expertise of EncubeEthicals, a pharmaceutical powerhouse since 1998, the brand benefits from the expertise of over 1,400 professionals, including more than 200 R&D specialists and a robust team of quality experts. With a presence in over 50 countries, Encube’s commitment to excellence in topical formulations adds deep credibility to Soframycin’s legacy. Now, as the brand enters the digital space, BigTrunk Communications will lead the charge in reimagining Soframycin’s story—creating modern, relatable digital experiences that stay true to its heritage.
“As we take Soframycin into its next chapter of growth, embracing digital media is not just a strategy but a necessity. We wanted a partner who could translate our scientific credibility into engaging, relatable content for today’s audience,” said Soframycin vice president – marketing, Ajay Rawal. “BigTrunk’s deep understanding of healthcare communications and digital behavior makes them the ideal partner to build meaningful narratives around wound care, trust, and wellbeing.”
“Soframycin is more than a product—it’s a legacy deeply rooted in care and science,” added BigTrunk Communications founder & managing director Bharat Subramaniam. “We’re excited to take on this responsibility of guiding a heritage brand into the digital world. Our focus will be on creating contextual storytelling and purpose-driven campaigns that bring Soframycin closer to Indian families, both old and new.”







